LYVE1 and myocardial infarction: Moreover, the ESV in Lyve1-mutant hearts was significantly increased (Figure 7, C–G, and Supplemental Table 1; day 7 control, 36.47% ± 8.26%, Lyve1–/–, 34.34% ± 6.17%; day 21 control, 43.33% ± 9.00%, Lyve-1–/–, 47.18% ± 7.92%; P ≤ 0.05; day 7 vs. 21 Lyve1–/–), and there was evidence of LV wall thinning (Supplemental Videos 1 and 2), which is known to contribute to a decline in cardiac function after MI.